


Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-00311

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.
Substitute for form 1449A1PTO



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/889,331
Filing Date	July 13, 2001
First Named Inventor	Young, A
Group Art Unit	
Examiner Name	
Attorney Docket Number	030639.0031.UTL

Sheet	1	of	4
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MMDDYYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Cod& (if knowit)			
SWL		5,264,372		Beaumont et al.	11/23/1993	
SWL		5,424,286		Eng	6/13/1995	
SWL		5,686,511		Bobo	11/11/1997	

Examiner Initials	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MMDDYYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	Office	Number Kind Cod& (if knowit)				
	AU	199731732	Roeche Diagnostics GmbH	1/5/98		
	WO	95/07098	Amylin Pharmaceuticals, Inc.	3/16/95		
SWL	WO	98/05351	Amylin Pharmaceuticals, Inc.	2/12/98		
SWL	WO	98/30231	Amylin Pharmaceuticals, Inc.	7/16/98		
	WO	99/07404	Amylin Pharmaceuticals, Inc.	2/18/99		
	WO	99/25727	Amylin Pharmaceuticals, Inc.	5/27/99		
	WO	99/25728	Amylin Pharmaceuticals, Inc.	5/27/99		
	WO	99/40788	Amylin Pharmaceuticals, Inc.	8/19/99		
SWL	WO	00/41546	Amylin Pharmaceuticals, Inc.	7/20/00		
SWL	WO	00/41548	Amylin Pharmaceuticals, Inc.	7/20/00		

Examiner Signature		Date Considered	7-4-02
--------------------	--	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, ~ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete, Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A1PT0

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Complete if Known

Application Number	09/889,331
Filing Date	July 13, 2001
First Named Inventor	Young, A
Group Art Unit	
Examiner Name	
Attorney Docket Number	030639.0031.UTL

Sheet	3	of	4
-------	---	----	---

SWL	4, an Exendin-3 Analogue, from <i>Heloderma suspectum</i> Venom," J. Biol. Chem., 267(11):7402-05 (1992).
	ENG, J., "Prolonged Effect of Exendin-4 on Hyperglycemia of db/db mice," <u>Diabetes</u> , 45(Supp 2):152A (abstract 554) (1996).
SWL	FRANCIS, et al., "PEGylation of Cytokines and Other Therapeutic Proteins and Peptides: the Importance of Biological Optimisation of Coupling Techniques," International Journal of Hematology, 68(1):1-18(1998).
	GLAUSER, et al., "Intravenous Glucagon in the Management of Esophageal Food Obstruction," JACEP, 8:228-231(1979).
SWL	GOKE, et al. "Exendin-4 Is a High Potency Agonist and Truncated Exendin-(9-39)-amide an Antagonist at the Glucagon-like Peptide 1-(7-36)-amide Receptor of Insulin-secreting β -Cells," J. Biol. Chem., 268(26):19650-55 (1993).
	MALHOTRA, et al., "Exendin-4, a New Peptide from <i>Heloderma suspectum</i> Venom, Potentiates Cholecystokinin-Induced Amylase Release from Rat Pancreatic Acini," <u>Regulatory Peptides</u> , 41:149-56 (1992).
	O'HALLORAN, et al., "Glucagon-like Peptide-1 (7-36)-NH ₂ : A Physiological Inhibitor of Gastric Acid Secretion in Man," J. Endocrinol. 126(1):169-73 (1990).
	ØRSKOV, et al., "Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7-36 Amide and Glucagonlike Peptide-1 7-37 in Healthy Subjects Are Indistinguishable," <u>Diabetes</u> , 42:658-61 (1993)
	PASSA, P., et al., "Mechanisms Suppressing Glucagon Secretion in Glucagonomas," <u>Diabetologia</u> , 19(3):305 [abstract 298] (1980)
SWL	RAUFMAN, et al. "Truncated Glucagon-like Peptide-1 Interacts with Exendin Receptors in Dispersed Acini from Guinea Pig Pancreas," J. Biol. Chem., 267(30):21432-37 (1992).
	SCHEPP, et al., "Exendin-4 and Exendin-(9-39)NH ₂ : Agonist and Antagonist, Respectively, at the Rat Parietal Cell

Examiner Signature		Date Considered	7-4-02
--------------------	---	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, ~ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete, Time will vary depending upon the needs of the individual case. Any comments on e amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-00311

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A1PTO


INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/889,331
Filing Date	July 13, 2001
First Named Inventor	Young, A
Group Art Unit	
Examiner Name	
Attorney Docket Number	030639.0031.UTL

Sheet 2 of 4



OTHER NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BYRNE, M.M., et al., "Lessons from Human Studies with Glucagon-like Peptide-1: Potential of the Gut Hormone for Clinical Use," <u>Front. Diabetes</u> , 13:219-33 (1997).	*
swL		CHEN, Y.E., et al., "Tissue-specific Expression of Unique mRNAs That Encode Proglucagon-derived Peptides or Exendin 4 in the Lizard," <u>Journal of Biological Chemistry</u> , 272(7): 4108-4115 (1997).	
swL		CREUTZFELDT, W.O.C., et al., "Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-like Peptide I(7-36) Amide in Type I Diabetic Patients," <u>Diabetes Care</u> 19(6):580-6 (1996).	
swL		D'ALESSIO, et al., "Elimination of the Action of Glucagon-like Peptide 1 Causes an Impairment of Glucose Tolerance after Nutrient Ingestion by Healthy Baboons," <u>J. Clin. Invest.</u> , 97:133-38 (1996).	
		EGAN, J.M., et al., "Glucagon-like Peptide-1 Restores Acute Phase Insulin Release to Aged Rats," <u>Diabetologia</u> , 40(Supp 1):A130 abstract 505 (1997).	
		DANIEL, O. et al., "Use of Glucagon in the Treatment of Acute Diverticultis," <u>British Medical Journal</u> , 3:720-2, (1974).	
		EISSELE, et al., "Rat Gastric Somatostatin and Gastrin Release: Interactions of Exendin-4 and Truncated Glucagon-like Peptide-1 (GLP-1) Amide," <u>Life Sci.</u> , 55(8):629-34 (1994).	
swL		ENG, J., et al., "Purification and Structure of Exendin-3, a New Pancreatic Secretagogue Isolated from <i>Heloderma horridum</i> Venom," <u>J. Biol. Chem.</u> , 265(33):20259-62 (1990)	
		ENG, J., et al., "Isolation and Characterization of Exendin-	
Examiner Signature			Date Considered 7-4-02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, ~ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete, Time will vary depending upon the needs of the individual case. Any comments on e amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-00311

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A1PT0

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Complete if Known

Application Number	09/889,331
Filing Date	July 13, 2001
First Named Inventor	Young, A
Group Art Unit	
Examiner Name	
Attorney Docket Number	030639.0031.UTL



		Receptor for Glucagon-like Peptide-1-(7-36)NH ₂ , " Eur. J. Pharm., 269:183-91 (1994).	
		SCHJOLDAGER, et al., "GLP-1 (Glucagon-like Peptide 1) and Truncated GLP-1, Fragments of Human Proglucagon, Inhibit Gastric Acid Secretion in Humans," Dig. Dis. Sci., 34(5):703-8 (1989).	
		SINGH, et al., "Use of ¹²⁵ I-[Y ³⁹]exendin-4 to Characterize Exendin Receptors on Dispersed Pancreatic Acini and Gastric Chief Cells from Guinea Pig, " Regul. Pep., 53:47-59 (1994).	
		STOWER, et al., "A Trial of Glucagon in the Treatment of Painful Biliary Tract Disease, " Br. J. Surg., 69:591-2 (1982).	
SWL		THORENS, "Expression Cloning of the Pancreatic β Cell Receptor for the Gluco-Incretin Hormone Glucagon-like Peptide 1," Proc. Natl. Acad. Sci. USA, 89:8641-45 (1992).	
		TURTON, M.D., et al., "A Role for Glucagon-like Peptide-1 in the Central Regulation of Feeding," Nature, 379:69-72 (1996).	
		WETTERGREN, et al., "Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man," Dig. Dis. Sci., 38(4):665-73 (1993).	
		WILLMS, et al., "Gastric Emptying, Glucose Responses, and Insulin Secretion after a Liquid Test Meal: Effects of Exogenous Glucagon-Like Peptide-1 (GLP-1)-(7-36) Amide in Type 2 (Noninsulin-Dependent) Diabetic Patients," J. Clin. Endocrinol. Metab., 81(1):327-32 (1996).	

Examiner Signature		Date Considered	7-4-02
--------------------	--	-----------------	--------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on e amount of time you are required to complete this form should be sent to the Chief Information Officer, U, S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, ~ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on e amount of time you are required to complete this form should be sent to the Chief Information Officer, U, S. Patent and Trademark Office, Washington, DC 20231.

NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.